About Enzon Pharmaceuticals (OTCMKTS:ENZN)
Enzon Pharmaceuticals, Inc. receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products: PegIntron, Sylatron, Macugen and CIMZIA. The Company has no clinical operations and limited corporate operations. PegIntron is used both as a monotherapy and in combination with REBETOL (ribavirin) capsules for the treatment of chronic hepatitis C. Macugen is used for the treatment of neovascular (wet) age-related macular degeneration. Sylatron is used for the treatment of melanoma. CIMZIA is used for the treatment of moderate to severe rheumatoid arthritis and Crohn's disease. CIMZIA is a biologic medicine that counteracts tumor necrosis factor (or TNF), which promotes inflammation of the joints in rheumatoid arthritis.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$8.38 million
Price / Sales1.16
Price / CashN/A
Book Value$0.23 per share
Price / Book0.96
Return on Equity3.27%
Return on Assets3.12%
Enzon Pharmaceuticals (OTCMKTS:ENZN) Frequently Asked Questions
What is Enzon Pharmaceuticals' stock symbol?
Enzon Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ENZN."
How often does Enzon Pharmaceuticals pay dividends? What is the dividend yield for Enzon Pharmaceuticals?
Enzon Pharmaceuticals announced a dividend on Tuesday, August 15th. Investors of record on Wednesday, August 30th will be paid a dividend of $0.15 per share on Thursday, September 28th. The ex-dividend date of this dividend is Friday, September 29th. View Enzon Pharmaceuticals' Dividend History.
How were Enzon Pharmaceuticals' earnings last quarter?
Enzon Pharmaceuticals Inc (OTCMKTS:ENZN) announced its quarterly earnings data on Wednesday, August, 10th. The biotechnology company reported $0.02 earnings per share for the quarter. The biotechnology company earned $2.27 million during the quarter. Enzon Pharmaceuticals had a net margin of 4.00% and a return on equity of 3.27%. View Enzon Pharmaceuticals' Earnings History.
When will Enzon Pharmaceuticals make its next earnings announcement?
Who are some of Enzon Pharmaceuticals' key competitors?
Some companies that are related to Enzon Pharmaceuticals include Cellectar Biosciences (CLRB), Bio-Path (BPTH), Soligenix (SNGX), Invivo Therapeutics (NVIV), Auris Medical (EARS), Xenetic Biosciences (XBIO), Fibrocell Science (FCSC), Achieve Life Sciences (ACHV), Orexigen Therapeutics (OREX), Ritter Pharmaceuticals (RTTR), OHR Pharmaceutical (OHRP), Acura Pharmaceuticals (ACUR), Heat Biologics (HTBX), Jaguar Health (JAGX), Cytori Therapeutics (CYTX), Windtree Therapeutics (WINT), Eyegate Pharmaceuticals (EYEG) and OpGen (OPGN).
Who are Enzon Pharmaceuticals' key executives?
Enzon Pharmaceuticals' management team includes the folowing people:
- Jonathan N. Christodoro, Chairman of the Board (Age 41)
- Andrew D. Rackear J.D., Chief Executive Officer, Secretary (Age 60)
- Richard L. Feinstein, Chief Financial Officer, Vice President - Finance (Age 71)
- Odysseas D. Kostas M.D., Director (Age 43)
- Jennifer I. McNealey, Director (Age 42)
How do I buy Enzon Pharmaceuticals stock?
Shares of Enzon Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Enzon Pharmaceuticals' stock price today?
One share of Enzon Pharmaceuticals stock can currently be purchased for approximately $0.22.
How big of a company is Enzon Pharmaceuticals?
Enzon Pharmaceuticals has a market capitalization of $9.73 million and generates $8.38 million in revenue each year. Enzon Pharmaceuticals employs 5 workers across the globe.
How can I contact Enzon Pharmaceuticals?
Enzon Pharmaceuticals' mailing address is 20 Commerce Drive Suite 135, Cranford NJ, 07016. The biotechnology company can be reached via phone at 732-980-4500 or via email at [email protected]
MarketBeat Community Rating for Enzon Pharmaceuticals (ENZN)MarketBeat's community ratings are surveys of what our community members think about Enzon Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Enzon Pharmaceuticals (OTCMKTS:ENZN) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Enzon Pharmaceuticals (OTCMKTS:ENZN) Earnings History and Estimates Chart
Enzon Pharmaceuticals (OTCMKTS ENZN) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/23/2018|| || || || || || || || |
|8/10/2017||Q2 2017||$0.09||$6.78 million||View||N/A|
|5/11/2017||Q1 2017||$0.01||$1.44 million||View||N/A|
|3/24/2017||Q4 2016||($0.10)||$0.85 million||View||N/A|
|11/10/2016||Q3 2016||$0.02||$1.99 million||View||N/A|
|8/10/2016||Q3 2016||$0.02||$2.27 million||View||N/A|
|5/9/2016||Q1 2016||$0.03||$3.27 million||View||N/A|
|3/21/2016||Q4 2015||$0.28||$3.16 million||View||N/A|
|11/6/2015||Q3 2015||($0.04)||$3.84 million||View||N/A|
|8/7/2015||Q2 2015||$0.09||$5.19 million||View||N/A|
|5/13/2015||Q1 2015||$0.16||$5.26 million||View||N/A|
|3/5/2015||Q4 2014||$0.13||$6.27 million||View||N/A|
|11/6/2014||Q3 2014||$0.17||$8.16 million||View||N/A|
|8/8/2014||Q2 2014||$0.16||$7.77 million||View||N/A|
|5/9/2014||Q1 2014||$0.19||$8.98 million||View||N/A|
|3/14/2014||Q4 2013||$0.12||$7.43 million||View||N/A|
|11/12/2013||Q3 2013||$0.13||$8.83 million||View||N/A|
|8/6/2013||Q2 2013||$0.09||$8.06 million||View||N/A|
|5/10/2013||Q1 2013||$0.05||$10.40 million||$10.18 million||View||N/A|
|3/18/2013||Q4 2012||($0.11)||$10.01 million||$10.65 million||View||N/A|
Enzon Pharmaceuticals (OTCMKTS:ENZN) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Enzon Pharmaceuticals (OTCMKTS:ENZN) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Enzon Pharmaceuticals (OTCMKTS ENZN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.06%
Institutional Ownership Percentage: 0.09%
Enzon Pharmaceuticals (OTCMKTS ENZN) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|11/28/2016||Carl C Icahn||Major Shareholder||Buy||694,023||$0.41||$284,549.43|| |
|9/19/2013||Robert Lebuhn||Director||Sell||55,926||$1.72||$96,192.72|| |
|8/10/2012||Robert Lebuhn||Director||Sell||1,933||$6.58||$12,719.14|| |
Enzon Pharmaceuticals (OTCMKTS ENZN) News Headlines
Enzon Pharmaceuticals (OTCMKTS:ENZN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Enzon Pharmaceuticals (OTCMKTS:ENZN) Income Statement, Balance Sheet and Cash Flow Statement
Enzon Pharmaceuticals (OTCMKTS ENZN) Stock Chart for Tuesday, February, 20, 2018